Oncothyreon enjoys Puma's success

Shares of Oncothyreon (ONTY +16.1%) jump on 7x surge in volume today. The cancer therapeutics firm also has a HER2 inhibitor (ONT-380) in development.

Investors are falling all over themselves to buy into Puma Biotechnology (PBYI +292.5%) after it announced positive results from a Phase 3 clinical trial evaluating its HER2 inhibitor PB272 (neratinib) as a treatment for breast cancer.

Comments (1)
  • Aiken
    , contributor
    Comments (3) | Send Message
    The profiles of ONT-380 is totally different from neratinib. ONT-380 is able to penetrate BBB so the developer of this drug focuses it on the brain metastatic breast cancer.
    1 Aug 2014, 05:52 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs